NeoPharm kept at strong buy by JMP

NeoPharm, Inc. was maintained by JMP Securities analyst Charles C. Duncan at a strong buy rating with a price target of $19 per share. NeoPharm announced Monday that its enrollment in a phase III trial of cintredekin besudotox for a highly malignant form of brain cancer was lower than expectations. JMP said it believes the trial remains on track to be fully enrolled by the end of the year. Shares of the Lake Forest, Ill.-based biopharmaceutical company were down $0.43, or 3.35%, at $12.42 on volume of 520,780 shares versus the three-month running average of 235,459 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.